Concepts (59)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 4 | 2021 | 272 | 1.560 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2021 | 110 | 0.960 |
Why?
|
| Mitochondria | 2 | 2019 | 643 | 0.920 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 102 | 0.690 |
Why?
|
| Mitochondrial Dynamics | 1 | 2018 | 17 | 0.620 |
Why?
|
| MicroRNAs | 2 | 2021 | 447 | 0.610 |
Why?
|
| Dopaminergic Neurons | 1 | 2018 | 46 | 0.600 |
Why?
|
| Oxidative Stress | 2 | 2019 | 718 | 0.580 |
Why?
|
| Histones | 1 | 2013 | 111 | 0.430 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 163 | 0.400 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 19 | 0.200 |
Why?
|
| Neuroprotection | 1 | 2021 | 28 | 0.190 |
Why?
|
| Prodrugs | 1 | 2021 | 54 | 0.190 |
Why?
|
| Central Nervous System | 1 | 2021 | 107 | 0.180 |
Why?
|
| Aspirin | 1 | 2021 | 295 | 0.170 |
Why?
|
| Hyperhomocysteinemia | 1 | 2019 | 15 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 240 | 0.170 |
Why?
|
| Signal Transduction | 2 | 2019 | 2689 | 0.160 |
Why?
|
| Retinal Ganglion Cells | 1 | 2019 | 72 | 0.160 |
Why?
|
| Fumarates | 1 | 2016 | 28 | 0.140 |
Why?
|
| Animals | 5 | 2021 | 20881 | 0.130 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 43 | 0.130 |
Why?
|
| Neurons | 1 | 2021 | 881 | 0.130 |
Why?
|
| Humans | 7 | 2021 | 68618 | 0.120 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 11 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 317 | 0.110 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 193 | 0.100 |
Why?
|
| Mice, Knockout | 3 | 2021 | 1692 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 786 | 0.090 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 2 | 2021 | 22 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2550 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1745 | 0.060 |
Why?
|
| Risk Factors | 1 | 2013 | 5731 | 0.060 |
Why?
|
| Mice | 3 | 2021 | 8474 | 0.050 |
Why?
|
| Antioxidant Response Elements | 1 | 2021 | 10 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 137 | 0.050 |
Why?
|
| Rats | 2 | 2021 | 5300 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 322 | 0.050 |
Why?
|
| Ependymoglial Cells | 1 | 2019 | 7 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 147 | 0.040 |
Why?
|
| Glycolysis | 1 | 2019 | 79 | 0.040 |
Why?
|
| Electroretinography | 1 | 2019 | 122 | 0.040 |
Why?
|
| Cell Count | 1 | 2019 | 248 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2019 | 143 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1553 | 0.040 |
Why?
|
| Retina | 1 | 2019 | 252 | 0.040 |
Why?
|
| Maleates | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1851 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2016 | 100 | 0.030 |
Why?
|
| Tyrosine | 1 | 2016 | 196 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 230 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1293 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 2791 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 14862 | 0.020 |
Why?
|
| Male | 1 | 2021 | 37321 | 0.010 |
Why?
|
| Female | 1 | 2021 | 38074 | 0.010 |
Why?
|